SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
June 11 2024 - 8:30AM
SeaStar Medical Holding Corporation (Nasdaq: ICU), a
commercial-stage medical device company developing proprietary
solutions to reduce the consequences of hyperinflammation on vital
organs, announces that its patented, cell-directed, extracorporeal
Selective Cytopheretic Device (SCD) is being featured in two
presentations at the 42nd Vicenza Course AKI-CRRT-ECOS and Critical
Care Nephrology conference today, June 11, 2024. The International
Vicenza Course – a scientific program that integrates
industry-sponsored symposia, meet-the-expert sessions and short
presentations – is being held June 11-13 in Vicenza, Italy.
“The prestigious International Vicenza Course is
known for showcasing breakthroughs in the field of extracorporeal
organ support. It is an honor to be invited to showcase our SCD
technology by Dr. Claudio Ronco, director of the International
Renal Research Institute of Vicenza (IRRIV) and internationally
recognized thought leader in the field,” said Kevin Chung, MD,
SeaStar Medical Chief Medical Officer. “Our SCD offers a
groundbreaking approach to treating critically ill pediatric and
adult AKI patients. We are excited to share the potential of our
therapy to save lives and eliminate dialysis dependency with the
audience of global nephrologists and intensivists attending this
conference.”
The presentations featuring SeaStar Medical’s
SCD are as follows:
- “A Novel Selective Cytopheretic
Device” being presented by Stuart Goldstein, MD, Cincinnati
Children’s Hospital, principal investigator of SeaStar Medical’s
pediatric AKI pilot studies and member of SeaStar Medical’s
Scientific Advisory Board. The discussion will be held during the
“News in Pediatric CRRT” session that is jointly sponsored by
Cincinnati Children’s Hospital and the IRRIV.
- “Cell-directed Therapy: Promising
Approach to Sepsis and Other Dysregulated Immunological States,
Including Acute Kidney Injury” presented in a SeaStar
Medical-sponsored symposium by SCD inventor H. David Humes, MD,
Professor, Division of Nephrology, Internal Medicine, University of
Michigan and SeaStar Medical Scientific Advisor.
About the 42nd
Vicenza Course AKI-CRRT-ECOS and Critical Care
NephrologyThe 42nd edition of the International Vicenza
Course focuses on new developments in the areas of technology,
pharmacology, clinical trials and consensus definitions in critical
care nephrology and related therapies. The conference offers the
most updated information on scientific advances and breakthrough
technologies, together with basic concepts and practical hands-on
instructions. The goal is to improve knowledge and skills in AKI
and related diagnostic procedures and therapeutic strategies
including new pharmacological options and new extracorporeal
therapies.
About the Selective Cytopheretic Device
(SCD)The SCD is a patented cell-directed extracorporeal
device that employs immunomodulating technology to selectively
target proinflammatory neutrophils and monocytes during continuous
kidney renal therapy (KRT) and reduces the hyperinflammatory milieu
including the cytokine storm that causes inflammation, organ
failure and possible death in critically ill patients. Unlike
pathogen removal and other blood-purification tools, the device is
integrated with KRT hemofiltration systems to selectively target
and transition proinflammatory monocytes to a reparative state and
promote activated neutrophils to be less inflammatory. The SCD
selectively targets the most highly activated proinflammatory
neutrophils and monocytes. These cells are then returned back into
the body through the blood, and the body is signaled to lower its
inflammatory environment and focus on repair. This unique
immunomodulation approach may promote long-term organ recovery and
eliminate the need for future KRT, including dialysis.
About SeaStar MedicalSeaStar
Medical is a commercial-stage medical technology company that is
redefining how extracorporeal therapies may reduce the consequences
of excessive inflammation on vital organs. SeaStar Medical’s novel
technologies rely on science and innovation to provide life-saving
solutions to critically ill patients. The Company is developing and
commercializing cell-directed extracorporeal therapies that target
the effector cells that drive systemic inflammation, causing direct
tissue damage and secreting a range of pro-inflammatory cytokines
that initiate and propagate imbalanced immune responses. For more
information visit www.seastarmedical.com or visit us on LinkedIn or
X.
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1955. These forward-looking
statements include, without limitation, SeaStar Medical’s
expectations with respect to the ability of SCD to treat patients
with AKI and other diseases; the expected regulatory approval
process and timeline for commercialization; and the ability of
SeaStar Medical to meet the expected timeline. Words such as
“believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
and similar expressions are intended to identify such
forward-looking statements. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to significant risks and uncertainties that
could cause the actual results to differ materially from the
expected results. Most of these factors are outside SeaStar
Medical’s control and are difficult to predict. Factors that may
cause actual future events to differ materially from the expected
results include, but are not limited to: (i) the risk that SeaStar
Medical may not be able to obtain regulatory approval of its SCD
product candidates; (ii) the risk that SeaStar Medical may not be
able to raise sufficient capital to fund its operations, including
current or future clinical trials; (iii) the risk that SeaStar
Medical and its current and future collaborators are unable to
successfully develop and commercialize its products or services, or
experience significant delays in doing so, including failure to
achieve approval of its products by applicable federal and state
regulators, (iv) the risk that SeaStar Medical may never achieve or
sustain profitability; (v) the risk that SeaStar Medical may not be
able to access funding under existing agreements; (vi) the risk
that third-parties suppliers and manufacturers are not able to
fully and timely meet their obligations, (vii) the risk of product
liability or regulatory lawsuits or proceedings relating to SeaStar
Medical’s products and services, (viii) the risk that SeaStar
Medical is unable to secure or protect its intellectual property,
and (ix) other risks and uncertainties indicated from time to time
in SeaStar Medical’s Annual Report on Form 10-K, including those
under the “Risk Factors” section therein and in SeaStar Medical’s
other filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assumes no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Investor Contact:LHA Investor
Relations Jody Cain (310)
691-7100 Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Jul 2024 to Aug 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Aug 2023 to Aug 2024